Syndax Pharmaceuticals Inc
For the period ended Sep 30, 2024. Filed Nov 5, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 5, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
Trading Arrangements
During the quarter ended September 30, 2024, our directors and officers (as defined in Rule 16a-1(f) under the Exchange Act) adopted orterminated contracts, instructions or written plans for the purchase or sale of our securities as set forth in the table below.
| Type of Trading Arrangement | ||||||
|---|---|---|---|---|---|---|
| Name and Position · Action · Adoption/Termination Date · Rule 10b5-1* · Non- Rule 10b5-1** · Total Shares of Common Stock to be Sold · Total Shares of Common Stock to be Purchased · Expiration Date | ||||||
| Michael A. MetzgerChief Executive Officer, Director | Adoption*** | 8/2/2024 | X | 171,195 | - | 9/10/2025 |
- Contract, instructions, or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act.
** “Non-Rule 10b5-1 trading arrangement” as defined in Item 408(c) of Regulation S-K under the Exchange Act.
*** The selling start date of Mr. Metzger’s plan is January 2025, after the Company’s current NDA PDUFA date of December 26, 2024, and the plan solely includes equity grants with expiration dates prior to September 10, 2025.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.